Marksans Pharma (MARKSANS) Q3 24/25 earnings summary

Executive summary

• Achieved record quarterly PAT in Q3 FY25, with revenue up 16.3% YoY, led by 37% YoY growth in the U.S. and improved U.K. performance.

• Gross margin expanded by 279 bps YoY due to improved product mix and lower import/raw material prices, despite higher freight and employee costs from facility ramp-up.

• EBITDA margin declined YoY due to investments in the acquired facility and higher freight costs.

• Strategic focus on new product launches, facility ramp-up, and achieving INR 3,000 crore revenue milestone.

• Board and Audit Committee reviewed and approved results on February 11, 2025; auditors issued unmodified review conclusions.

Financial highlights

• Q3 FY25 consolidated revenue: ₹6,818.46 million (INR 682 crore), up 16.3% YoY; U.S./North America revenue: ₹352.9 crore, up 37% YoY.

• Q3 FY25 gross profit: ₹383.5 crore, up 22.4% YoY; gross margin: 56.2% (+279bps YoY).

• Q3 FY25 EBITDA: ₹138.8 crore, up 4.3% YoY; EBITDA margin: 20.4%, down 234 bps YoY.

• Q3 FY25 PAT: ₹105.1 crore, up 26.6% YoY; consolidated net profit: ₹860.00 million; EPS: ₹2.3.

• 9M FY25 revenue: ₹1,914 crore, up 18.4% YoY; PAT: ₹292 crore, up 23% YoY; cash balance: ₹669 crore as of Dec 31, 2024.

Outlook and guidance

• Performance expected to improve with continued facility ramp-up and new product launches.

• Freight and employee costs expected to stabilize, reducing margin drag.

• U.K. market expected to accelerate with robust product pipeline and regulatory approvals; medium- to long-term growth targeted in Europe.

• Capacity sufficient for INR 3,000–4,000 crore revenue; further expansion planned as business approaches INR 4,000 crore.

• Aims to double U.S. revenue and become a top 5 private label OTC company in North America within 2 years.